




CERE-110, A Genetically Engineered Adeno-Associated Virus-Based Vector to Deliver Human β -Nerve Growth Factor

Protocol: #0401-623

Principal Investigator: David A. Bennett, M.D.
Director, Rush Alzheimer's Disease Center
Chicago, IL


Neurosurgeon: Roy Bakay, M.D.
Chicago Institute of Neurosurgery and
Neuroresearch, Chicago, IL

Sponsor: Ceregene Inc.
San Diego, CA



RAC Presentation Agenda


- **Introduction and Product Description**
 - Jeffrey M. Ostrove, Ph.D. President, Ceregene Inc
- **Alzheimer's Disease and Clinical Protocol**
 - David A. Bennett, M.D. Rush University Medical Center
- **Update on OBA Protocol #9906-322, *ex vivo* delivery of NGF to Patients with Alzheimer's Disease**
 - Mark Tuszynski, M.D. University of California, San Diego
- **CERE-110 Non-Clinical Data Summary**
 - Raymond T. Bartus, Ph.D. VP R&D, Ceregene Inc




The Structure of the CERE-110 Vector Genome



AAV-2 based vector (ITRs & Rep/Cap)



CERE-110 Production



PROCESS STEPS

Ceregene has developed a scalable, cGMP manufacturing process

In-process and final product samples are tested according to FDA guidelines

